Abstract
Advanced age is a relevant risk factor for the heart failure (HF). The development of new pharmacological and non-pharmacological approaches has determined an improvement in survival of patients with HF, leading to the selection of an older and frailer population with HF. The clinical approach to such a complex population should require clear indications to assist physicians during their daily practice, but there is a huge lack of evidence regarding the treatment of HF in the oldest among the elderly patient population. In addition, the co-occurrence of specific conditions that are extremely prevalent in older individuals with HF, such as cognitive impairment, comorbidities, and polypharmacy, can further complicate the clinical man agement of this condition. Thus, a multidisciplinary approach with the goal of recognizing and treating conditions associated with HF may be necessary to improve the quality of care and to reduce expenditures. Several studies have assessed the effect of a comprehensive geriatric assessment and management on quality of care in HF patients, demonstrating a substantial improvement in patient outcomes and administration of the appropriate drug treatment.
Keywords: Heart failure, elderly, polypharmacy, multidimensional approach, oldest old.
Current Pharmaceutical Design
Title:Treating Heart Failure in Older and Oldest Old Patients
Volume: 21 Issue: 13
Author(s): Davide Liborio Vetrano, Fabrizia Lattanzio, Anna Maria Martone, Francesco Landi, Vincenzo Brandi, Eva Topinkova and Graziano Onder
Affiliation:
Keywords: Heart failure, elderly, polypharmacy, multidimensional approach, oldest old.
Abstract: Advanced age is a relevant risk factor for the heart failure (HF). The development of new pharmacological and non-pharmacological approaches has determined an improvement in survival of patients with HF, leading to the selection of an older and frailer population with HF. The clinical approach to such a complex population should require clear indications to assist physicians during their daily practice, but there is a huge lack of evidence regarding the treatment of HF in the oldest among the elderly patient population. In addition, the co-occurrence of specific conditions that are extremely prevalent in older individuals with HF, such as cognitive impairment, comorbidities, and polypharmacy, can further complicate the clinical man agement of this condition. Thus, a multidisciplinary approach with the goal of recognizing and treating conditions associated with HF may be necessary to improve the quality of care and to reduce expenditures. Several studies have assessed the effect of a comprehensive geriatric assessment and management on quality of care in HF patients, demonstrating a substantial improvement in patient outcomes and administration of the appropriate drug treatment.
Export Options
About this article
Cite this article as:
Vetrano Liborio Davide, Lattanzio Fabrizia, Martone Maria Anna, Landi Francesco, Brandi Vincenzo, Topinkova Eva and Onder Graziano, Treating Heart Failure in Older and Oldest Old Patients, Current Pharmaceutical Design 2015; 21 (13) . https://dx.doi.org/10.2174/1381612821666150130124021
DOI https://dx.doi.org/10.2174/1381612821666150130124021 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Technological Innovations in Magnetic Resonance for Early Detection of Cardiovascular Diseases
Current Pharmaceutical Design Effects of Thiazolidinediones Beyond Glycaemic Control
Current Pharmaceutical Design Statins and Vulnerable Plaque
Current Pharmaceutical Design New Recombinant Serotypes of AAV Vectors
Current Gene Therapy Hirudo medicinalis: Avascular Tissues for Clear-Cut Angiogenesis Studies?
Current Pharmaceutical Design Preface
Current Cardiology Reviews Role of microRNAs in Hepatic Stellate Cells and Hepatic Fibrosis: An Update
Current Pharmaceutical Design Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology Supraventricular Tachycardia in Fetus: How Can We Treat ?
Current Pharmaceutical Design Chloride Channels − New Targets for the Prevention of Stroke
Current Vascular Pharmacology A synopsis on the linkage between age-related dementias and vascular disorders
CNS & Neurological Disorders - Drug Targets Anti-atherosclerotic Effects of Spice-Derived Phytochemicals
Current Medicinal Chemistry The Role of Chronic Periodontitis in Prevention and Treatment of Head and Neck Cancers
Current Cancer Therapy Reviews The Endocannabinoid System in the Cancer Therapy: An Overview
Current Medicinal Chemistry The Pathophysiology of Heart Failure in Children: The Basics
Current Cardiology Reviews Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) Tissue Factor and Hypertension
Current Hypertension Reviews Remodeling of Protein Aggregates by Hsp104
Protein & Peptide Letters Modulators of Networks: Molecular Targets of Arterial Calcification Identified in Man and Mice
Current Pharmaceutical Design miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets